Pharmacy Place, Llc; Decision and Order

Document Headings Document headings vary by document type but may contain the following: the agency or agencies that issued and signed a document the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to the agency docket number / agency internal file number the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details. Department of Justice Drug Enforcement Administration I. Introduction On November 17, 2021, the United States Department of Justice, Drug Enforcement Administration (Agency) issued an Order to Show Cause and Immediate Suspension of Registration (collectively, OSC/ISO) to Pharmacy Place, LLC, of Houston, Texas (Respondent). [ 1 ] OSC/ISO, at 1, 10-11. The OSC/ISO immediately suspended, and proposed the revocation of, Respondent's Drug Enforcement Administration (DEA or Government) certificate of registration, No. FP8885785 (registration), pursuant to 21 U.S.C. 824(d) and (a)(4) , respectively, “because . . . [Respondent's] continued registration constitutes `an imminent danger to the public health or safety'” and “because . . . [Respondent's] continued registration is inconsistent with the public interest, as that term is defined in 21 U.S.C. . . . [823(g)(1)].”  2 Id. at 1. The OSC/ISO more specifically alleges that, according to an “independent pharmacy expert retained by the DEA” who “reviewed patient profile data, Texas Prescription Monitoring Program data, and prescriptions reported as filled by Respondent,” Respondent “filled many controlled substance prescriptions outside the usual course of pharmacy practice” and “in contravention of . . . [its] `corresponding responsibility' under 21 CFR 1306.04(a) ” from March 16, 2020, through August 19, 2021. Id. at 2. The OSC/ISO also alleges that Respo…